期刊
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
卷 204, 期 6, 页码 S84-S88出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2011.03.002
关键词
influenza; oseltamivir; pregnancy; treatment
资金
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [HD047905, HD047891, HD047892]
- Office of Research on Women's Health, National Institutes of Health (NIH)
- NICHD, NIH
- NIH National Center for Research Resources [UL1RR025014]
- Centers for Disease Control and Prevention
- Association of Maternal and Child Health Programs
We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据